Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Kestra Medical Technologies, Ltd. held its 2025 annual general meeting of shareholders on September 3, 2025. A total of 48,835,102 common shares were voted in person or by proxy, representing approximately 95% of the 51,348,656 shares outstanding and entitled to vote as of July 7, 2025.
Shareholders elected Conor Hanley and Elizabeth Kwo as Class I directors to serve until the 2028 annual meeting and until their successors are duly elected and qualified. The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending April 30, 2026 was ratified. Shareholders also approved the company’s 2025 Employee Stock Purchase Plan.